Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Molecular Quality Controls Market
The molecular quality controls market is projected to expand from USD 257.09 million in 2025 to USD 520.09 million by 2035, reflecting a compound annual growth rate (CAGR) of 7.3%. This growth is driven by the increasing adoption of molecular diagnostics in healthcare, rising prevalence of infectious diseases and chronic conditions, and continuous advancements in technology and automation. Molecular quality controls, which include standardized substances for evaluating the performance and accuracy of molecular diagnostic tests, are essential for ensuring reliable and reproducible results across laboratories.
The market serves a broad range of end users, including diagnostic laboratories, hospitals, IVD manufacturers, and academic institutions, with applications spanning infectious disease diagnostics, oncology testing, and genetic testing.
Market size
Growth trajectory through 2035
Molecular Quality Controls Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Million
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 Multiplex Controls for Infectious Diseases
- Several companies have introduced multiplex controls capable of validating assays for multiple pathogens simultaneously, improving efficiency and reducing costs for laboratories.
-
Development 02 Controls for Next-Generation Sequencing (NGS)
- Providers are developing controls tailored for NGS platforms, addressing the growing demand for high-throughput sequencing in research and clinical settings.
-
Development 03 Partnerships Between IVD Manufacturers and Quality Control Providers
- Collaborations are enabling the integration of quality controls into diagnostic workflows, enhancing the accuracy and reliability of testing platforms.
-
Development 04 Expansion into Emerging Markets
- Key players are forming alliances with local distributors and healthcare providers to strengthen their presence in regions such as Asia-Pacific and Latin America.
Emerging opportunities added
- Emerging markets in Asia-Pacific and Latin America Rapidly growing healthcare infrastructure and increasing investment in diagnostic technologies in these regions present significant opportunities for market expansion.
- Integration with digital health and AI The adoption of digital health platforms and artificial intelligence in diagnostics can enhance the utility of molecular quality controls by enabling real-time performance monitoring and predictive analytics.
- Development of multiplex and multi-analyte controls Advances in assay design are driving demand for controls that can validate multiple targets simultaneously, offering laboratories greater efficiency and cost savings.
- Collaborations between IVD manufacturers and quality control providers Partnerships can accelerate innovation, improve product offerings, and streamline the integration of quality controls into diagnostic workflows.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $257.1 Mn
- CAGR
- 7.30%
- Expansion
- 2.0×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- Diagnostic Laboratories: Facilities performing routine
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- Regulatory hurdles
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Multiplex Controls for Infectious Diseases: Several companies have introduced multiplex controls capable of validating assays for multiple pathogens simultaneously, improving efficiency and reducing costs for laboratories
+5 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 70-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Molecular Quality Controls Market today ($257.1 Mn base), and how fast will it grow at 7.3% CAGR through 2035?
- Which of assays.Instrument Specific (PCR, testing methodologies holds the largest share, and how do the growth rates diverge?
- How is demand distributed across bacteria, including carrier screening, rare disease diagnostics applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Increasing adoption of molecular diagnostics) and top restraints (led by Regulatory hurdles), with quantified CAGR impact?
- What regulatory shifts and 6 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Increasing adoption of molecular diagnostics The rapid integration of molecular diagnostics in healthcare settings is a primary driver for demand in molecular quality controls. These tests, which detect and analyze genetic material to identify diseases or pathogens, require standardized controls to ensure accuracy and reliability.
- Rising prevalence of infectious diseases and chronic conditions The growing burden of infectious diseases and chronic illnesses necessitates robust diagnostic frameworks, increasing the need for validated quality control materials to maintain test performance.
- Advancements in technology and automation Innovations in molecular testing platforms, including automation and next-generation sequencing, are creating demand for high-quality controls that can validate these advanced systems and ensure consistent results.
- Stringent regulatory requirements Healthcare authorities worldwide impose rigorous standards for diagnostic testing, compelling laboratories and manufacturers to adopt compliant quality control measures to meet regulatory expectations.
- Expansion of personalized medicine and precision healthcare The shift toward tailored therapeutic approaches, particularly in oncology and genetic testing, relies on accurate molecular diagnostics, thereby driving demand for reliable quality controls.
- Growth in genomics and proteomics R&D Increased research activity in genomics and proteomics is expanding the application of molecular quality controls, as these fields require precise and reproducible testing methodologies.
Restraints
Holding it back
- Regulatory hurdles The approval and compliance processes for molecular quality controls can be lengthy, delaying market entry for new products and increasing operational costs for manufacturers.
- High development and validation costs Producing molecular quality controls involves stringent processes, including analyte selection, batch validation, and adherence to industry standards, which contribute to elevated production costs.
- Supply chain challenges Disruptions in the supply of critical reagents and materials can impact the production and availability of molecular quality controls, particularly for specialized analytes.
- Limited standardization across regions Variations in regulatory frameworks and testing standards across different geographies can create barriers to market expansion and complicate the adoption of universal quality control solutions.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Increasing adoption of molecular diagnostics | +3.3% | Global | 2025–2035 |
| Rising prevalence of infectious diseases and chronic conditions | +2.0% | Global | 2025–2035 |
| Advancements in technology and automation | +1.6% | Global | 2025–2035 |
| Stringent regulatory requirements | +1.1% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Regulatory hurdles | −1.3% | Global | 2025–2029 |
| High development and validation costs | −0.9% | Global | 2025–2029 |
| Supply chain challenges | −0.7% | Global | 2025–2029 |
The molecular quality controls market is segmented by product type, application, analyte type, and end user.
Revenue share by type · 2025 base year
% OF $257.1 MN MOLECULAR QUALITY CONTROLS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $257.1 Mn Molecular Quality Controls Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
assays.Instrument Specific (PCR
-
testing methodologies
By application
-
bacteria
-
including carrier screening
-
rare disease diagnostics
By end-user industry
-
Diagnostic Laboratories: Facilities performing routine
-
validating diagnostic assays
-
quality control materials.Academic
-
proteomics
-
molecular diagnostics.Others: Includes blood banks
-
public health agencies
-
biopharmaceutical companies
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $257.1 MN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~46.1% in 2025. The largest market, driven by advanced healthcare infrastructure, high adoption of molecular diagnostics, and strong presence of key industry players. The region benefits from robust regulatory frame…
Per-region detail
-
North America
The largest market, driven by advanced healthcare infrastructure, high adoption of molecular diagnostics, and strong presence of key industry players. The region benefits from robust regulatory frameworks and significant investment in research and development
-
Europe
A mature market with stringent regulatory standards and high demand for quality control solutions. Growth is supported by the increasing prevalence of chronic diseases and the expansion of personalized medicine
-
Asia-Pacific
The fastest-growing region, fueled by expanding healthcare access, rising healthcare expenditure, and increasing adoption of molecular diagnostics. Countries such as China, Japan, and India are key contributors to market growth
-
Latin America
Growth is driven by improving healthcare infrastructure and rising awareness of the importance of accurate diagnostics. However, market expansion is constrained by economic factors and regulatory challenges
-
Middle East & Africa
A developing market with significant potential, particularly in regions with growing healthcare investments. The demand for molecular quality controls is increasing as diagnostic capabilities expand
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The molecular quality controls market is moderately consolidated, with a mix of global players and specialized providers. Key companies focus on product innovation, strategic partnerships, and compliance with regulatory standards to maintain their market position.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
• What is the worth of global Molecular quality controls market?
The Molecular quality controls market size had crossed USD 154.43 Billion in 2020 and is expected to grow till USD 278.21 billion by 2029. -
• Which is the largest regional market for Molecular quality controls market?
The Largest Regional market for Molecular quality controls market is APAC having a market share of 39%. -
• What is the CAGR of Molecular quality controls market?
The global Molecular quality controls market registered a CAGR of 6.90% from 2022 to 2029. -
• Which are the top companies to hold the market share in Molecular quality controls market?
Key players profiled in the report include F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Randox Laboratories Ltd., LGC Limited, Abbott Laboratories, Fortress Diagnostics, SERO AS, Anchor Molecular, Ortho-Clinical Diagnostics, Inc. , Quidel Corporation , Sun Diagnostics, LLC , Seegene Inc. , ZeptoMetrix, LLC, Qnostics ,Bio-Techne Corporation, Microbiologics, Inc., Microbix Biosystems Inc., SpeeDx Pty. Ltd., Maine Molecular Quality Controls, Inc., and Grifols, S.A.
The Molecular Quality Controls Market is projected to reach $520.1 Mn by 2035, up from $257.1 Mn in 2025 — a 7.30% CAGR equating to roughly 2.0× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.